Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

How many relevant SARS-CoV-2 variants might we expect in the future?

View ORCID ProfileRoberto Littera, View ORCID ProfileMaurizio Melis
doi: https://doi.org/10.1101/2021.11.17.21266463
Roberto Littera
1Complex Structure of Medical Genetics, R. Binaghi Hospital, Local Public Health and Social Care Unit (ASSL) of Cagliari, Sardinian Regional Company for the Protection of Health (ATS Sardegna), Cagliari, Italy
2Association for the Advancement of Research on Transplantation O.d.V., non-profit organisation, Cagliari, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Roberto Littera
Maurizio Melis
2Association for the Advancement of Research on Transplantation O.d.V., non-profit organisation, Cagliari, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Maurizio Melis
  • For correspondence: maurizio.melis@gmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Objectives The emergence of new SARS-CoV-2 variants is a major challenge in the management of Covid-19 pandemic. A crucial issue is to quantify the number of variants which may represent a potential risk for public health in the future.

Methods We fitted the data on the most relevant SARS-CoV-2 variants recorded by the World Health Organization (WHO). The function exploited for the fit is related to the total number of infected subjects in the world since the start of the epidemic.

Results We found that the number of relevant SARS-CoV-2 variants up to November 2021 was about 44. Moreover, the number of new relevant variants per ten million cases turned out to be 1.64 in November 2021, slightly decreased in comparison to the value of 2.29 in March 2020.

Conclusions Our simple mathematical model can evaluate the number of relevant SARS-CoV-2 variants as the cumulative number of cases increase worldwide and may represent a useful tool in planning strategies to effectively contrast the pandemic.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The authors received no specific funding for this work

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

https://www.who.int/en/activities/tracking-SARS-CoV-2-variants

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • E-mail addresses: roby.litter{at}gmail.com (R. Littera), maurizio.melis{at}gmail.com (M. Melis).

Data Availability

All data referred to in the manuscript are available online at https://www.who.int/en/activities/tracking-SARS-CoV-2-variants

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted November 21, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
How many relevant SARS-CoV-2 variants might we expect in the future?
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
How many relevant SARS-CoV-2 variants might we expect in the future?
Roberto Littera, Maurizio Melis
medRxiv 2021.11.17.21266463; doi: https://doi.org/10.1101/2021.11.17.21266463
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
How many relevant SARS-CoV-2 variants might we expect in the future?
Roberto Littera, Maurizio Melis
medRxiv 2021.11.17.21266463; doi: https://doi.org/10.1101/2021.11.17.21266463

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (227)
  • Allergy and Immunology (501)
  • Anesthesia (110)
  • Cardiovascular Medicine (1233)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (529)
  • Epidemiology (10012)
  • Forensic Medicine (5)
  • Gastroenterology (498)
  • Genetic and Genomic Medicine (2448)
  • Geriatric Medicine (236)
  • Health Economics (479)
  • Health Informatics (1636)
  • Health Policy (751)
  • Health Systems and Quality Improvement (635)
  • Hematology (248)
  • HIV/AIDS (532)
  • Infectious Diseases (except HIV/AIDS) (11860)
  • Intensive Care and Critical Care Medicine (625)
  • Medical Education (252)
  • Medical Ethics (74)
  • Nephrology (268)
  • Neurology (2277)
  • Nursing (139)
  • Nutrition (350)
  • Obstetrics and Gynecology (452)
  • Occupational and Environmental Health (534)
  • Oncology (1245)
  • Ophthalmology (375)
  • Orthopedics (133)
  • Otolaryngology (226)
  • Pain Medicine (155)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (729)
  • Pharmacology and Therapeutics (311)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2280)
  • Public and Global Health (4828)
  • Radiology and Imaging (834)
  • Rehabilitation Medicine and Physical Therapy (490)
  • Respiratory Medicine (650)
  • Rheumatology (283)
  • Sexual and Reproductive Health (237)
  • Sports Medicine (226)
  • Surgery (266)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)